EC
JANX icon

EntryPoint Capital’s Janux Therapeutics JANX Stock Holding History

EntryPoint Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,225
Closed -$655K – 803
2024
Q4 		$655K Buy
+12,225
New +$647K 0.28% 34
2024
Q3 		– Sell
-1,649
Closed -$69.1K – 984
2024
Q2 		$69.1K Buy
+1,649
New +$77.4K 0.03% 975

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

EntryPoint Capital's JANX Position: Q1 2025 in Review

EntryPoint Capital sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 12,225 shares — an estimated $655K sold.

EntryPoint Capital first reported a position in JANX in Q2 2024 and held it in 2 quarters. The position peaked at $655K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • EntryPoint Capital reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 12,225 Janux Therapeutics shares in Q1 2025, an estimated $655K.
  • EntryPoint Capital first reported a position in Janux Therapeutics in Q2 2024 and held it in 2 quarters.
  • EntryPoint Capital's Janux Therapeutics position peaked at $655K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.